of the University of Pennsylvania–CHOP Clinical Translational Science Award (CTSA). Dr. Adamson was recruited from the National Cancer Institute (NCI) where he was an Investigator in the Pharmacology and Experimental Therapeutics Section of the Pediatric Oncology Branch. He was a member of the IOM committee on shortening the timeline for new cancer treatments and co-edited the report Making Better Cancer Drugs for Children (2005).

Carolyn Asbury, Sc.M.P.H., Ph.D., is a Senior Consultant at the Dana Foundation (a New York-based non-profit that supports translational and clinical research in neuroscience, immunology, and neuroimmunology) and is also an adjunct Senior Fellow, Leonard Davis Institute of Health Economics at the University of Pennsylvania. She has served as Vice Chair and Chair of the Board of the National Organization for Rare Disorders, is a member of the Board of the U.S. Pharmacopeia, and is a Trustee of the College of Physicians of Philadelphia. Dr. Asbury has a master’s degree in public health and a doctorate in health systems business. She served as an advisor on market exclusivity, tax credit, and regulatory provisions of the 1983 Orphan Drug Act and subsequently authored the book Orphan Drugs: Medical versus Market Value. She has also authored several journal articles and book chapters on orphan drug issues and policies. Prior to her role at Dana, she was Senior Program Officer at the Robert Wood Johnson Foundation and then Director of the Health and Human Services Program at the Pew Charitable Trusts.

Paul Citron, M.S.E.E., retired in 2003 as Vice President of Technology Policy and Academic Relations at Medtronic, Inc., where he was previously Vice President of Science and Technology. He had responsibility for corporate-wide assessment and coordination of technology and for establishing and prioritization of corporate research. Currently he is adjunct professor at the Jacobs School of Engineering, University of California San Diego and an advisor to the Harvard-MIT Division of Health Sciences and Technology. He is also an advisor to several firms in the biotechnology sector. Mr. Citron has a B.S. and M.S. in electrical engineering. He was elected a Founding Fellow of the American Institute of Medical and Biological Engineering. He has authored numerous publications and holds eight U.S. medical device patents. He is a member of the National Academy of Engineering (NAE) and serves on the advisory group of the NAE’s Center for Engineering, Ethics, and Society. He served on the IOM committee on postmarket surveillance of pediatric medical devices.

Peter B. Corr, Ph.D., is a Founder and General Partner of Celtic Therapeutics LLLP, a private equity firm focused on the development of innovative